Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.460

0.0%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	7/31/2007 9:34:38 AM
	of 368

Piper Jaffray Reiterates Their Outperform Rating on Sangamo BioSciences (SGMO) and Raises Their Price Target 07-30-2007 Piper Jaffray reiterates their Outperform rating on Sangamo BioSciences (NASDAQ: SGMO) and raises their price target from $12.50 to $14. The firm said, "Our new target is based on a projected enterprise value of $500 million (up from $400 million) to which we add mid- 2008E cash of $65 million. We continue to value the Phase II diabetic neuropathy and PAD programs at $200 million each and are adding $100 million for the CCR5 HIV program, which we anticipate will enter the clinic this year. At this point, we assign no value for the glioblastoma program until more feasibility data is available."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next